Results 1 to 10 of about 602,975 (317)
The Economic Burden of Adults with Major Depressive Disorder in the United States (2010 and 2018)
PharmacoEconomics (Auckland), 2021 The incremental economic burden of US adults with major depressive disorder (MDD) was estimated at $US210.5 billion in 2010 (year 2012 values). Following a similar methodology, this study updates the previous findings with more recent data to report the ...
P. Greenberg +6 more
semanticscholar +1 more source
Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized Clinical Trial.
Journal of the American Medical Association (JAMA), 2023 Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD.
C. Raison +33 more
semanticscholar +1 more source
The genetic basis of major depressive disorder
Molecular Psychiatry, 2023 The genetic dissection of major depressive disorder (MDD) ranks as one of the success stories of psychiatric genetics, with genome-wide association studies (GWAS) identifying 178 genetic risk loci and proposing more than 200 candidate genes. However, the
J. Flint
semanticscholar +1 more source
Molecular pathways of major depressive disorder converge on the synapse
Molecular Psychiatry, 2022 Major depressive disorder (MDD) is a psychiatric disease of still poorly understood molecular etiology. Extensive studies at different molecular levels point to a high complexity of numerous interrelated pathways as the underpinnings of depression. Major
G. Fries +3 more
semanticscholar +1 more source
Molecular Psychiatry, 2022 The emerging understanding of gut microbiota as ‘metabolic machinery’ influencing many aspects of physiology has gained substantial attention in the field of psychiatry. This is largely due to the many overlapping pathophysiological mechanisms associated
A. McGuinness +15 more
semanticscholar +1 more source
C-Reactive Protein as a Biomarker for Major Depressive Disorder?
International Journal of Molecular Sciences, 2022 The etiopathogenesis of depression is not entirely understood. Several studies have investigated the role of inflammation in major depressive disorder. The present work aims to review the literature on the association between C-Reactive Protein (CRP) and
L. Orsolini +4 more
semanticscholar +1 more source
Translational Psychiatry, 2021 Psilocybin has shown promise for the treatment of mood disorders, which are often accompanied by cognitive dysfunction including cognitive rigidity.
Manoj K. Doss +10 more
semanticscholar +1 more source
Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder
JAMA psychiatry, 2020 This randomized clinical trial examines the efficacy of psilocybin as an adjunct to psychotherapy and other treatments for major depressive disorder.
Alan K. Davis +7 more
semanticscholar +1 more source
Nature Communications, 2021 Major depressive disorder (MDD) has been shown to be associated with structural abnormalities in a variety of spatially diverse brain regions. However, the correlation between brain structural changes in MDD and gene expression is unclear.
Jiao Li +10 more
semanticscholar +1 more source
Disrupted intrinsic functional brain topology in patients with major depressive disorder
Molecular Psychiatry, 2021 Aberrant topological organization of whole-brain networks has been inconsistently reported in studies of patients with major depressive disorder (MDD), reflecting limited sample sizes.
Hong Yang +72 more
semanticscholar +1 more source